133 related articles for article (PubMed ID: 17669147)
1. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
Larré S; Hamadeh H; Azzouzi AR; Vallancien G; Cochand-Priollet B; Cancel-Tassin G; Cussenot O
BJU Int; 2007 Sep; 100(3):679-84. PubMed ID: 17669147
[TBL] [Abstract][Full Text] [Related]
2. [Genetic determinants of anatomical variants of the prostate].
Hamadeh H; Larré S; Azzouzi AR; Cancel-Tassin G; Vallancien G; Cochand-Priollet B; Cussenot O
Prog Urol; 2008 Apr; 18(4):214-22. PubMed ID: 18501301
[TBL] [Abstract][Full Text] [Related]
3. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.
Azzouzi AR; Cochand-Priollet B; Mangin P; Fournier G; Berthon P; Latil A; Cussenot O
Eur J Endocrinol; 2002 Oct; 147(4):479-84. PubMed ID: 12370109
[TBL] [Abstract][Full Text] [Related]
4. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
5. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.
Yu MW; Yang YC; Yang SY; Cheng SW; Liaw YF; Lin SM; Chen CJ
J Natl Cancer Inst; 2001 Nov; 93(21):1644-51. PubMed ID: 11698569
[TBL] [Abstract][Full Text] [Related]
6. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
7. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
9. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
10. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
12. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
13. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
14. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
15. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
16. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
17. The Presence of Clitoromegaly in the Nonclassical Form of 21-Hydroxylase Deficiency Could Be Partially Modulated by the CAG Polymorphic Tract of the Androgen Receptor Gene.
Moura-Massari VO; Cunha FS; Gomes LG; Bugano Diniz Gomes D; Marcondes JA; Madureira G; de Mendonca BB; Bachega TA
PLoS One; 2016; 11(2):e0148548. PubMed ID: 26848581
[TBL] [Abstract][Full Text] [Related]
18. Inherited variation in hormone-regulating genes and prostate cancer survival.
Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement.
Shibata A; Stamey TA; McNeal JE; Cheng I; Peehl DM
J Urol; 2001 Oct; 166(4):1560-4. PubMed ID: 11547131
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
Renko O; Savolainen ER; Loikkanen I; Paavonen TK; Vaarala MH
DNA Cell Biol; 2008 Feb; 27(2):109-13. PubMed ID: 17979523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
